Alnylam's New Drug May Prove Threat to Sanofi, Regeneron, Amgen

  • Drug cut bad cholesterol about as much as newest treatments
  • Patients could get shots quarterly rather than every two weeks

A drug from Alnylam Pharmaceuticals Inc. and Medicines Co. cut bad cholesterol levels among patients in a small trial by about as much as new treatments from Sanofi, Regeneron Pharmaceuticals Inc. and Amgen Inc., with far less frequent dosing.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.